Barinthus Biotherapeutics (BRNS) EPS (Weighted Average and Diluted) (2020 - 2026)
Barinthus Biotherapeutics (BRNS) reported EPS (Weighted Average and Diluted) of -$0.14 for Q1 2026, up 71.43% on a YoY basis from -$0.08 in Q1 2025, and up 48.15% quarter-over-quarter from -$0.27 in Q4 2025.
Barinthus Biotherapeutics (BRNS) EPS (Weighted Average and Diluted) (2020 - 2026) Analysis & Trends
Barinthus Biotherapeutics has reported EPS (Weighted Average and Diluted) for 7 years, with the latest figure at -$0.14 in Q1 2026.
- For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) rose 71.43% year-over-year to -$0.14; the trailing twelve-month figure through Mar 2026 stood at -$1.29 (up 21.34% YoY), and the FY2025 full-year result was -$1.64, down 5.81% from the prior year.
- EPS (Weighted Average and Diluted) for Q1 2026 stood at -$0.14, up from -$0.27 in the prior quarter.
- The five-year high for EPS (Weighted Average and Diluted) was $0.41 in Q2 2022, with the low at -$0.62 in Q2 2023.
- Historically, EPS (Weighted Average and Diluted) has averaged -$0.3 across 5 years, with a median of -$0.4 in 2024.
- Annual changes were most pronounced in 2022 — EPS (Weighted Average and Diluted) surged 269.23% — and 2023, when it tumbled 805.88%.
- Barinthus Biotherapeutics' EPS (Weighted Average and Diluted) stood at -$0.55 in 2022, then advanced by 18.18% to -$0.45 in 2023, then declined by 13.33% to -$0.51 in 2024, then surged by 47.06% to -$0.27 in 2025, then surged by 48.15% to -$0.14 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.14 (Q1 2026), -$0.27 (Q4 2025), and -$0.36 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | 3.06 |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | 0.00 |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -0.61 |
| 10 | Barinthus Biotherapeutics | 27.08 Mn | -40.03 Mn | - | -0.14 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.14 |
| Dec 31, 2025 | -0.27 |
| Sep 30, 2025 | -0.36 |
| Jun 30, 2025 | -0.52 |
| Mar 31, 2025 | -0.49 |
| Dec 31, 2024 | -0.51 |
| Sep 30, 2024 | -0.21 |
| Jun 30, 2024 | -0.43 |
| Mar 31, 2024 | -0.40 |
| Dec 31, 2023 | -0.45 |
| Sep 30, 2023 | -0.37 |
| Jun 30, 2023 | -0.62 |
| Mar 31, 2023 | -0.48 |
| Dec 31, 2022 | -0.55 |
| Sep 30, 2022 | 0.22 |
| Jun 30, 2022 | 0.41 |
| Mar 31, 2022 | 0.07 |
| Dec 31, 2021 | -0.38 |
| Sep 30, 2021 | -0.13 |
| Jun 30, 2021 | -0.64 |